Back to Search
Start Over
Germany : New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD-treated RMS Patients Mount Protective Antibody Response to Common Vaccines
- Source :
- Mena Report. March 5, 2021
- Publication Year :
- 2021
-
Abstract
- Merck, a leading science and technology company, today announced the presentation of a new analysis from the MAGNIFY-MS study on MAVENCLAD (cladribine tablets) in patients with relapsing multiple sclerosis (RMS) [...]
Details
- Language :
- English
- ISSN :
- 22190112
- Database :
- Gale General OneFile
- Journal :
- Mena Report
- Publication Type :
- News
- Accession number :
- edsgcl.653979836